Dicerna (DRNA): Partnerships Expected to Follow After Settlement - SunTrust

April 20, 2018 1:46 PM

SunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $15 price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found